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Pharmacokinetic (PK) similarity was assessed among PF-05280586 (a proposed biosimilar) vs. rituximab sourced from the Euro-
pean Union (rituximab-EU) and the United States (rituximab-US). Pharmacodynamics (PD), overall safety and immunogenicity
were also evaluated.
METHODS
Patients with active rheumatoid arthritis on a background of methotrexate and inadequate response to one or more tumour
necrosis factor antagonist therapies were randomized to intravenous PF-05280586, rituximab-EU or rituximab-US 1000mg doses
on study days 1 and 15.
RESULTS
A total of 220 patients were randomized to receive study treatment as assigned. Of these, 198 met per-protocol population
criteria for inclusion in the PK data analysis. PF-05280586, rituximab-EU and rituximab-US exhibited similar PK proﬁles following
administration of assigned study drug on days 1 and 15. The 90% conﬁdence intervals of test-to-reference ratios for Cmax, AUCT,
AUC0–∞ and AUC2-week were within the bioequivalence margin of 80.00–125.00% for comparisons of PF-05280586 with
rituximab-EU, PF-05280586 with rituximab-US, and rituximab-EU with rituximab-US. All treatments resulted in a rapid and pro-
found reduction in CD19+ B cells and sustained profound B cell suppression up to week 25. The incidence of antidrug antibody
(ADA) response (n = 7, 10 and 9 for PF-05280586, rituximab-EU and rituximab-US, respectively), time to ADA emergence and
ADA titres were similar across treatments. None of the ADA-positive samples was positive for neutralizing activity. No clinically
meaningful differences in adverse events were identiﬁed.
CONCLUSIONS
The study demonstrated PK similarity among PF-05280586, rituximab-EU and rituximab-US. In addition, all treatments showed
comparable CD19+ B cell depletion PD responses, as well as safety and immunogenicity proﬁles.© 2016 Pﬁzer Inc. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd
on behalf of British Pharmocological Society.
DOI:10.1111/bcp.12916
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S. Cohen et al.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Rituximab, a monoclonal antibody directed against the CD20 antigen of B cells, is indicated for non-Hodgkin’s lymphoma,
chronic lymphocytic leukaemia (with chemotherapy), rheumatoid arthritis (with methotrexate) and granulomatosis with
polyangiitis and microscopic polyangiitis (with glucocorticoids).
WHAT THIS STUDY ADDS
• This is the ﬁrst clinical report providing evidence of similarity of pharmacokinetics, pharmacodynamics, immunogenicity and
safety of PF-05280586 (a proposed biosimilar) vs. reference products rituximab-EU and rituximab-US.
• The results provide critical bridging data between the two reference products to allow use of a single reference product in future
phase III studies.Introduction
The term ‘biosimilar’ refers to a biologic product developed to
be highly similar to an existing licensed or approved biologic
product [1–4]. Biosimilars are expected to be an essential
component in enhancing patient access to these important,
often lifesaving biologic products. Biologics are large, struc-
turally complex molecules; even minor changes in the
manufacturing process could produce differences that can af-
fect the safety, immunogenicity and potency of the molecule
[3, 4]. Regulatory decisions for approval are based on the to-
tality of the evidence generated from a stepwise approach
that generally includes analytical, clinical pharmacokinetic
(PK), and efﬁcacy and safety studies intended to support the
demonstration of biosimilarity [1–4].
Rituximab is a genetically engineered chimeric murine/
human monoclonal immunoglobulin (Ig) G1κ antibody
directed against the CD20 antigen of B cells [5, 6]. It is indi-
cated for non-Hodgkin’s lymphoma, chronic lymphocytic
leukaemia (in combination with chemotherapy), rheumatoid
arthritis (RA; in combination with methotrexate) and granu-
lomatosis with polyangiitis and microscopic polyangiitis
(in combination with glucocorticoids) [5, 6]. The pathophys-
iology of RA is unknown, although it is thought to involve
activation of an innate immune response, including antigen
presentation and production of autoantibodies and cytokines
by B cells, and involvement of other key effector cells and
inﬂammatory modulators [7]. Thus, B cells are an important
and appropriate target for the treatment of RA, as conﬁrmed
by the efﬁcacy of rituximab since its approval in 2006.
PF-05280586, which is under development as a potential
biosimilar to rituximab, has the same primary amino acid
sequence, and similar physicochemical and in vitro functional
properties as rituximab [8, 9].
A multicentre, multinational, randomized, double-blind,
controlled trial (REFLECTIONS B328-01), reported herein, was
designed to demonstrate the PK similarity of PF-05280586 to
rituximab sourced from the European Union (rituximab-EU;
MabThera®, F. Hoffmann-La Roche, Basel, Switzerland [6])
and United States (rituximab-US; Rituxan®, Genentech Inc.,
South San Francisco, CA, USA [5]), and between rituximab-EU
and rituximab-US. The present study also evaluated the
pharmacodynamics (PD) and overall safety, tolerability and
immunogenicity of the study drugs.
Methods
This study was registered (ClinicalTrials.gov identiﬁer:
NCT01526057) and conducted in compliance with the130 Br J Clin Pharmacol (2016) 82 129–138Declaration of Helsinki and with all International Confer-
ence on Harmonisation Good Clinical Practice guidelines.
In addition, all local regulatory requirements were followed
and, in particular, those affording greater protection to the
safety of trial participants. The ﬁnal protocol, amendments
and informed consent documentation were reviewed and
approved by institutional review boards and/or independent
ethics committees at each investigational centre participat-
ing in the study. A signed and dated informed consent was
required from each patient before any screening procedures
were conducted.Study population and design
This was a phase I, double-blind, randomized, parallel-group,
three-arm trial (Figure S1). The primary objective was to dem-
onstrate PK similarity of PF-05280586, rituximab-EU and
rituximab-US in patients with active RA on a background
treatment of methotrexate and who had an inadequate re-
sponse to one or more tumour necrosis factor (TNF) antago-
nist therapies. Secondary objectives included assessing PD,
safety, tolerability and immunogenicity.
Rituximab produces profound and prolonged B cell deple-
tion [5, 6], precluding the conduct of PK studies in healthy
subjects. Its use in the present clinical trial population was
consistent with the labelled indication for rituximab-EU
and rituximab-US [5, 6]. Eligible participants were adults
(aged ≥18 years) with a conﬁrmed diagnosis of RA based
on 2010 American College of Rheumatology (ACR)/European
League Against Rheumatism classiﬁcation criteria [10].
Patients also had to meet class I, II or III of the ACR 1991 re-
vised criteria for global functional status in rheumatoid ar-
thritis [11]; have RA seropositivity, as documented by a
screening assessment for rheumatoid factor and/or anticyclic
citrullinated peptide antibodies; have active disease, as
deﬁned by the following: at least six tender/painful joints
(of 68 assessed) and six or more swollen joints (of 66 assessed)
at screening and baseline, high-sensitivity C-reactive protein
(CRP) greater than the upper limit of normal or a Patient’s
Global Assessment of Arthritis score ≥50 at screening, and
Disease Activity Score in 28 joints–CRP >3.2 at screening;
be on a stable dose of oral or parenteral methotrexate 10–25
mg per week (or as low as 7.5 mg per week, in the case of
prior poor tolerance) for at least 3 months and receiving the
stable dose for at least 4 weeks prior to the ﬁrst dose of the
study drug; and have an inadequate response, in the
opinion of the investigator, to one or more approved TNF an-
tagonist therapies, deﬁned as failure to achieve an adequate
clinical response during prior TNF antagonist therapy, relapse
PF-05280586, a potential biosimilar to rituximabfollowing a clinical response to TNF antagonist therapy or an
adverse event (AE) resulting in discontinuation of a TNF
antagonist.
Key exclusion criteria were: any prior treatment with
lymphocyte-depleting therapies; pregnancy, lactation or
unwillingness to use highly effective contraception for at
least 12months after the last dose of the investigational prod-
uct; inadequate bone marrow, liver, renal or immune system
functions at screening; evidence of untreated, inadequately
treated latent, or inadequately treated or active infection with
tuberculosis; known or screen-test positive for HIV, hepatitis
B or C, herpes zoster or herpes simplex; primary or secondary
immunodeﬁciency; history of recurrent inﬂammatory joint
disease other than RA; lymphoproliferative disorder; infec-
tion requiring hospitalization, parenteral antimicrobial
therapy within 3 months prior to the ﬁrst dose of the study
drug or judged clinically signiﬁcant by the investigator;
vaccination with live or attenuated vaccines within the 6
weeks prior to the ﬁrst dose of the study drug, or planned
administration during study participation or within 4 weeks
following discontinuation of study drug; current or recent
history of uncontrolled clinically signiﬁcant renal, hepatic,
haematological, gastrointestinal, endocrine, metabolic,
pulmonary, severe cardiac or neurological disease; addiction
or dependence on nonprescribed substances; history of a
malignancy, except for nonmelanoma skin cancer, in situ
carcinoma or those having nonhaematological tumours
treated with curative intent, with no evidence of disease for
5 years; signiﬁcant trauma or a surgical procedure within 4
weeks prior to the ﬁrst dose of the study drug; requirement
for treatment during the study with prohibited concomitant
medications; history of corticosteroid-induced psychosis or
signiﬁcant hyperglycaemia; known allergy or hypersensitiv-
ity to the active drug substance or excipients, or to murine,
chimeric, human or humanized proteins; or any other
severe acute or chronic medical or psychiatric condition or
laboratory abnormality that increased risk associated with
study participation or investigational product administration
or interfered with interpretation of the study results and, in
the judgement of the investigators, made the patient
inappropriate for entry into the study.
Eligible patients were randomized 1 : 1 : 1 via a computer-
generated randomization schedule to one course of PF-
05280586, rituximab-EU or rituximab-US, administered as
two 1000 mg intravenous (i.v.) doses on study days 1 and
15, in accordance with the treatment regimen in the
rituximab-EU and rituximab-US product labelling for RA [5,
6]. All patients received premedication with 100mg i.v. meth-
ylprednisolone (or its equivalent), an antipyretic agent and
an antihistaminic (e.g. acetaminophen and diphenhydra-
mine), in accordance with the accepted infusion protocols
for rituximab-EU and rituximab-US, prior to study drug infu-
sions to decrease the incidence and severity of acute infusion-
related reactions [5, 6]. Patients also continued the stable
background regimen of methotrexate.PK
The PK of PF-05280586, rituximab-EU and rituximab-US were
determined using serum samples collected predose (day 1,
within 1 h prior to the start of the ﬁrst infusion), and at 3 h(day 1, during the ﬁrst infusion), 4.25 h (day 1, immediately
prior to the end of the ﬁrst infusion), 72 h (day 4), 168 h
(day 8), 335 h (day 15, within 1.5 h prior to the start of the
second infusion), 337.5 h (day 15, during the second infu-
sion), 339.25 h (day 15, immediately prior to the end of the
second infusion), 408 h (day 18), 504 h (day 22), 672 h (day
29), 1344 h (day 57) and 2016 h (day 85) after the start of
the ﬁrst infusion on day 1. An additional drug concentration
sample was collected on day 169 to facilitate immunogenicity
assessment at low drug concentrations.
Samples were analysed using a validated, sensitive, spe-
ciﬁc enzyme-linked immunosorbent assay (ELISA) with a
lower limit of quantiﬁcation (LLOQ) of 100 ng ml–1. During
sample analysis, the precision (expressed as the coefﬁcient
of variation [CV%] of quality control samples) was 5.5% to
8.0% and the accuracy (expressed as the percentage relative
error [%RE] of quality control samples) was –1.8% to 7.0%.
Samples with serum rituximab concentrations below LLOQ
were set to zero for PK data analysis. Standard noncompart-
mental PK data analysis was conducted to estimate PK param-
eters using Phoenix® WinNonlin® (version 6.3; Pharsight
Corporation, Cary, NC, USA).
The primary PK endpoints were maximum serum concen-
tration (Cmax) and area under the serum concentration–time
proﬁle (AUC) from time 0 extrapolated to inﬁnite time
(AUC0–∞). Secondary PK endpoints were AUC from time 0 to
the last time point with a measurable concentration (AUCT),
AUC from time 0 to 2 weeks (AUC2-week), clearance (CL), vol-
ume at steady-state (Vss) and terminal half-life (t1/2). The per-
protocol population, deﬁned as all subjects who were ran-
domized to and received the full dose of the planned study
treatment and had no major protocol violations that affected
the PK analysis, was used for the PK analyses.PD
PD was evaluated using circulating CD19+ B cell counts (as a
surrogate marker for CD20+ B cells) and serum IgM. Blood
samples for CD19+ B cell counts were collected predose (day
1, within 1 h prior to the start of the ﬁrst infusion), and then
at 72 h (day 4), 168 h (day 8), 335 h (day 15, within 1.5 h be-
fore the second infusion), 504 h (day 22), 672 h (day 29),
1344 h (day 57), 2016 h (day 85), 2688 h (day 113), 3360 h
(day 141) and 4032 h (day 169). As a lowering of IgM levels
has been reported in patients treated with B cell-depleting
therapies, serum samples for evaluation of IgM levels were
collected at the same time points.
Blood samples were analysed for CD19+ B cell counts
using a laser scanning cytometry procedure (ApoCell Inc.,
Houston, TX, USA). CD19+ B cell count vs.time data were
analysed by standard noncompartmental methods using
Phoenix WinNonlin and used to calculate the mean mini-
mum CD19+ B cell count (Cmin,B cell) and median time to
Cmin,B cell (tmin B cell). The AUC for CD19+ B cell count vs.time
(AUCT, B cell) was estimated using linear trapezoidal linear in-
terpolation. The duration of B cell depletion (τB cell) was calcu-
lated as the time interval over which CD19+ B cell counts
were below the quantitation limit. CD19+ B cell counts for
those samples without corresponding absolute white blood
cell counts could not be calculated and were not included in
the data analysis.Br J Clin Pharmacol (2016) 82 129–138 131
S. Cohen et al.Serum samples were assayed for IgM concentrations at
CovanceCentral Laboratory Services Inc. (Indianapolis, IN,USA).
Immunogenicity
Serum samples for detecting antidrug antibodies (ADAs) and
neutralizing antibodies (Nabs) were collected on days 1
(predose), 15, 29, 57, 85 and 169. Immunogenicity sample
analyses followed a tiered approach of screening, conﬁrma-
tion and endpoint titre determination using two validated
electrochemiluminescent assays – one developed to detect
antibodies against PF-05280586 and the other to detect anti-
bodies against rituximab-EU and rituximab-US (QPS, LLC,
Newark, DE, USA). The two ADA assays demonstrated similar
performance characteristics during assay validation. The ADA
samples were ﬁrst analysed using the ADA assay speciﬁc for
the dosed product. Samples conﬁrmed positive for antibodies
to the dosed product were then assessed for cross-reactivity
using the alternative assay. Any samples conﬁrmed positive
for ADA were further tested for Nab using one of two (one
for PF-05280586 and one for rituximab-EU and rituximab-
US) cell-based Nab assays. Nab assays were based on the
functionality of Nab to inhibit the complement-dependent
cytotoxicity of PF-05280586, rituximab-EU and rituximab-
US on CD20+ WIL2-S cells (a human B lymphoma cell line).
Safety
The safety analysis was performed in all enrolled patients
who received the study drug (the modiﬁed intent-to-treat
population) and included AEs, electrocardiogram readings,
vital signs and clinical laboratory data. The type, incidence
and severity (mild, moderate or severe) of AEs, and the inves-
tigator’s opinion of the relationship to the study treatment of
any AEs, including adverse drug reactions, illnesses with
onset during the study, exacerbation of previous illnesses or
any clinically signiﬁcant changes in physical examination
or abnormal objective laboratory ﬁndings, were investigated.
Treatment-emergent AEs were deﬁned as any AE that oc-
curred during or after study drug administration of the ﬁrst
dose of the study drug or any pre-existing events that wors-
ened in severity after dosing.
Any AEs occurring postinfusion were reviewed as poten-
tial infusion-related reactions and veriﬁed by the reporting
investigator. All serious AEs (SAEs; i.e. events that resulted in
death, were life threatening, required inpatient hospitaliza-
tion or prolongation of existing hospitalization, resulted in
a persistent or signiﬁcant disability/incapacity, resulted in
congenital anomaly/birth defect, or jeopardized the patient
or required medical or surgical intervention to prevent one
of these outcomes) were to be reported immediately to the
sponsor, regardless of treatment or suspected relationship to
study drug. If an SAE occurred, the sponsor was to be notiﬁed
within 24 h of investigator awareness of the event.
Statistical analysis
Statistical analysis consisted of one-way analyses of variance
comparing the natural log-transformed PK parameters
(Cmax, AUC0–∞, AUC2-week and AUCT) for each pair-wise
comparison (PF-05280586 vs. rituximab-US, PF-05280586
vs. rituximab-EU, and rituximab-EU vs. rituximab-US). Esti-
mates of adjusted mean differences and corresponding132 Br J Clin Pharmacol (2016) 82 129–13890% conﬁdence intervals (CIs) were obtained from the
model and were exponentiated to provide estimates of the
ratio of adjusted geometric means and 90% CIs for the ra-
tios. PK similarity was considered to have been demon-
strated for a given test-to-reference comparison if the 90%
CI of the ratio was within the 80.00–125.00% bioequiva-
lence acceptance window.
A sample size of 65 patients per group (195 patients to-
tal) was required to provide approximately 89% power for
showing bioequivalence simultaneously for all three
AUC0–∞ comparisons, and approximately 97% power for
showing bioequivalence simultaneously for all three Cmax
comparisons. Consequently, the study was designed to have
at least 86% power overall to demonstrate PK similarity of
PF-05280586 to rituximab-EU and rituximab-US. This esti-
mate was based on the assumption that the true ratio of
PF-05280586 to rituximab-EU and rituximab-US for both
AUC0–∞ and Cmax was 1.00, and interpatient standard devia-
tions (SDs) were 0.34 for loge AUC0–∞ and 0.30 for loge Cmax.
Approximately 210 patients were to be randomized to en-
sure that at least 195 patients completed PK-related proce-
dures per protocol.Results
Patient demographics and disposition
A total of 220 patients were randomized to treatment groups
and received the study treatment as assigned (Figure 1). Base-
line demographics were generally similar among patients
(Table 1). The majority of patients were female [n = 170
(77.3%)] and white [n = 171 (77.7%)], with a mean age of
54.4 years, mean weight 83.13 kg and mean body mass index
30.07 kg m–2. Of these 220 patients, 198 met per-protocol
population criteria for inclusion in the PK data analysis. Pa-
tient disposition and ineligibility information for inclusion
in the per-protocol population is provided in Figure 1 and
Table S1.
A total of 18 (8.2%) patients discontinued before complet-
ing the study, including nine, three and six treated with
PF-05280586, rituximab-EU and rituximab-US, respectively
(Figure 1). No notable differences were observed across
groups with regard to reason for discontinuation of the study.
In the per-protocol population, there were no signiﬁcant im-
balances in demographic characteristics known to affect the
disposition of the study drugs among groups. Mean ± SD
body weights in the PF-05280586, rituximab-EU and
rituximab-US groups were 86.0 ± 22.2, 82.4 ± 20.4 and 79.9
± 21.4 kg, respectively.PK
The study drugs exhibited similar PK proﬁles, characterized
by a rapid increase in serum drug concentration during each
infusion on days 1 and 15, followed by a multiphasic decline
in drug concentrations after each infusion (Figure 2).
Mean peak concentrations ranged from 327 μg ml–1 to 357
μg ml–1 following the ﬁrst infusion and from 385 μg ml–1 to
421 μg ml–1 following the second infusion. The trough
Figure 1
Patient disposition. PK, pharmacokinetics. *Patients enrolled at one site were excluded because the validity of study conduct was not established.
(The vast majority of pharmacokinetic proﬁles from the site were contradictory to the known pharmacokinetic characteristics for rituximab.)
PF-05280586, a potential biosimilar to rituximabconcentration (Ctrough) levels immediately before the second
infusion were between 78.4 μg ml–1 and 91.8 μg ml–1.
Mean values and interpatient variability of the PK
parameters obtained from the concentration–time data of
the 12-week PK assessment period (Cmax, AUCT, AUC0–∞,
AUC2-week, CL, Vss and t1/2) were similar across all groups
(Table 2; Figure S2). The CV% was 26–38% for Cmax, 34–40%
for AUCT and 37–45% for AUC0–∞. Adjusted geometric means
and 90% CIs for the ratios of Cmax, AUCT, AUC0–∞ and AUC2-
week were within the acceptance window of 80.00–125.00%
for comparisons of PF-05280586 with rituximab-EU and
rituximab-US, and rituximab-EU with rituximab-US (Table 3).PD
Mean CD19+ B cell counts at baseline were 84–100 cells μl–1.
All treatments resulted in rapid CD19+ B cell depletion fol-
lowing dose administration on day 1 (Figure 3). By week 2,
mean CD19+ B cell count values had decreased by 98.2% to99.8% in all groups. CD19+ B cell counts remained sup-
pressed for the study duration (24 weeks). CD19+ B cell
counts recovered to at least 50% of baseline at the end of
treatment in three (4.1%) patients treated with PF-
05280586, six (8.1%) treated with rituximab EU and six
(8.2%) treated with rituximab-US.
In all three groups, Cmin,B cell values were below the
quantitation limit, with a tmin,B cell of 1 week. The mean
(±SD) area under the CD19+ B cell count vs. time curve
(AUCT, B cell) was 13 312 [±13 309 (n = 68)], 14 304
[±13146 (n = 69)] and 12 496 [±13500 (n = 67)] cells·day
ml–1 in the PF-05280586, rituximab-EU and rituximab-US
groups, respectively. The mean duration of B cell depletion
(τB cell) was 120–126 days. Overall, there were no observed
differences among groups in the CD19+ B cell count vs. time
proﬁle and the parameters determined.
There were no major variations in circulating IgM values
over time, with only small differences among the groups
(data not shown).Br J Clin Pharmacol (2016) 82 129–138 133
Table 1
Baseline demographics (mITT population)
PF-05280586 Rituximab-EU Rituximab-US
n = 73 n = 74 n = 73
Gender, n (%)
Male 14 (19.2) 17 (23.0) 19 (26.0)
Female 59 (80.8) 57 (77.0) 54 (74.0)
Age, mean ± SD, years 54.9 ± 11.52 54.9 ± 11.07 53.4 ± 11.87
Race, n (%)
White 56 (76.7) 57 (77.0) 58 (79.5)
Black 2 (2.7) 6 (8.1) 5 (6.8)
Asian 3 (4.1) 0 (0.0) 1 (1.4)
Other 12 (16.4) 11 (14.9) 9 (12.3)
Disease duration since ﬁrst diagnosis, mean ± SD, months 153.3 ± 99.34 140.6 ± 98.91 125.0 ± 96.83
Body mass index, mean ± SD, kg m–2 31.47 ± 8.133 29.76 ± 6.29 29.00 ± 6.74
mITT, modiﬁed intent-to-treat; SD, standard deviation.
S. Cohen et al.Immunogenicity
Immunogenicity was evaluated in all 220 patients who re-
ceived at least one dose of study drug for ADA responses
(Table S2). Thirteen patients (n = 4, n = 6 and n = 3 receiving
PF-05280586, rituximab-EU and rituximab-US, respectively)
tested positive for low titres of ADAs in samples collected at
baseline. Of these 13 patients, eight (n = 4, n = 3 and n = 1,
respectively) tested negative in all subsequent postdoseFigure 2
Individual and mean ± SD serum concentration–time proﬁles in patients wit
drugs on day 1 and day 15 (per-protocol population). Panels A–C: Green da
dashed lines represent patients testing negative for ADAs postdose. ADAs, a
134 Br J Clin Pharmacol (2016) 82 129–138samples. The other ﬁve patients who were positive for ADAs
at baseline also tested positive for ADAs at one or more time
points postdose.
A total of 26 patients (n = 7, n = 10 and n = 9 receiving PF-
05280586, rituximab-EU and rituximab-US, respectively)
tested positive for ADAs for at least one time point postdose.
Of these, 22 patients did not have detectable levels of ADAs
until day 85 or later (n = 6, n = 7 and n = 9, respectively). Inh rheumatoid arthritis receiving 1000 mg intravenous doses of study
shed lines represent patients testing positive for ADAs postdose; grey
ntidrug antibodies; SD, standard deviation
Table 2
Mean ± SD PK parameter estimates (per-protocol population)
PF-05280586 Rituximab-EU Rituximab-US
n = 68 n = 67 n = 63
Cmax, μg ml
–1 453 ± 153 422 ± 111 430 ± 163
AUC2-week, μg·h ml
–1 52, 100 ± 18, 000 49, 600 ± 14, 200 49, 200 ± 15, 900
AUCT, μg·h ml
–1
† 198, 000 ± 79, 600 188, 000 ± 64, 300 196, 000 ± 78, 300
AUC0-∞, μg·h ml
–1
‡ 213, 000 ± 90, 400 200, 000 ± 74,600 214, 000 ± 95, 300*
CL, ml h–1 kg–1 11.2 ± 4.91 11.4 ± 4.55 11.3 ± 4.87*
Vss, ml kg
–1 5490 ± 1740 5590 ± 1320 5810 ± 1590*
t½, h 434 ± 142 424 ± 125 456 ± 145*
AUC2-week, area under the serum concentration–time curve from time 0 to 2 weeks; AUCT, area under the serum concentration–time curve from time
0 to the last time point with a quantiﬁable concentration; AUC0–∞, area under the serum concentration–time curve from time 0 extrapolated to in-
ﬁnite time; CL, clearance; Cmax, maximum serum concentration; PK, pharmacokinetic; SD, standard deviation; t½, terminal elimination half-life; Vss,
volume of distribution at steady-state. *n = 62 as one patient missed multiple samples, for whom the terminal phase could not be determined ade-
quately. †AUCT was estimated based on the 12-week concentration–time data. When the additional drug concentration samples collected on day
169 were included in the calculation, themean (±SD) values of AUCT were 209,000 ± 87, 800 μg·h ml
–1, 198, 000 ± 70, 800 μg·hml–1 and 209, 000 ±
89, 800 μg·h ml–1 for PF-05280586, rituximab-EU and rituximab-US, respectively. ‡AUC0–∞was estimated based on the 12-week concentration–time
data. When the additional drug concentration samples collected on day 169 were included in the calculation, the mean (±SD) values of AUC0–∞were
213, 000 ± 89, 600 μg·h ml–1, 200, 000 ± 72, 500 μg·h ml–1 and 214, 000 ± 94, 000 μg·h ml–1 for PF-05280586, rituximab-EU and rituximab-US,
respectively.
Table 3
Statistical comparison of PK exposure parameters between test and reference products (per-protocol population)
Adjusted geometric mean
Test Reference Parameter Test Reference Ratio (%)* 90% CI (%)
PF-05280586 Rituximab-EU Cmax, μg ml
–1 432 409 105.67 96.91–115.21
AUC2-week, μg·h ml
–1 49 500 47 700 103.74 95.10–113.15
AUCT, μg·h ml
–1
† 184 000 178 000 103.36 92.81–115.12
AUC0–∞, μg·h ml
–1
‡ 196 000 188 000 104.19 92.75–117.06
PF-05280586 Rituximab-US Cmax, μg ml
–1 432 405 106.62 97.65–116.41
AUC2-week, μg·h ml
–1 49 500 46 900 105.56 96.64–115.30
AUCT, μg·h ml
–1
† 184 000 181 000 101.33 90.82–113.04
AUC0–∞, μg·h ml
–1
‡ 196 000 195 000 100.45 89.20–113.11
Rituximab-EU Rituximab-US Cmax, μg ml
–1 409 405 100.90 92.38–110.20
AUC2-week, μg·h ml
–1 47 700 46 900 101.76 93.13–111.18
AUCT, μg·h ml
–1
† 178 000 181 000 98.03 87.83–109.40
AUC0–∞, μg·h ml
–1
‡ 188 000 195 000 96.40 85.57–108.60
AUC2-week, area under the serum concentration–time proﬁle from time 0 to 2 weeks; AUCT, area under the serum concentration–time curve from time
0 to the last time point with a quantiﬁable concentration; AUC0-∞, area under the serum concentration–time curve from time 0 extrapolated to in-
ﬁnite time; CI, conﬁdence interval; Cmax, maximum serum concentration; PK, pharmacokinetic. *Test/reference ratio of adjusted geometric means.
†For AUCT calculated after inclusion of the additional drug concentration samples collected on day 169, the ratio (90% CI for ratio) was 103.26
(92.13–115.73), 100.45 (89.46–112.79) and 97.28 (86.60–109.27) for the comparisons of PF-05280586 vs. rituximab-EU, PF-05280586 vs. ritux-
imab-US, and rituximab-EU vs. rituximab-US, respectively. ‡For AUC0–∞ calculated after inclusion of the additional drug concentration samples
collected on day 169, the ratio (90% CI for ratio) was 104.19 (92.83–116.93), 100.21 (89.12–112.67) and 96.18 (85.51–108.19) for the compar-
isons of PF-05280586 vs. rituximab-EU, PF-05280586 vs. rituximab-US, and rituximab-EU vs. rituximab-US, respectively.
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Figure 3
CD19+ B cell count over time in the modiﬁed intent-to-treat population. B, baseline
S. Cohen et al.two patients (one each in the PF-05280586 and rituximab-
EU groups), ADAs ﬁrst emerged on day 15 and persisted un-
til the last sample collection on day 169. These patients also
had the highest ADA titres among all patients, with peak
titres of 4.24 detected on day 15 in one patient (rituxi-
mab-EU) and 4.57 on day 169 in the other (PF-05280586).
In addition, two patients receiving rituximab-EU had lower
titres of ADAs that were ﬁrst detected on days 29 and 57,
and persisted until the last sampling on day 169. On day
169, ADA samples were available from 55, 58 and 52
patients from the rituximab-US, rituximab-EU and PF-
05280586 groups, respectively. Among these patients, six
(10.9%), eight (13.8%) and six (11.5%) patients from the
rituximab-US, rituximab-EU and PF-05280586 groups, re-
spectively, tested positive for ADAs in the day 169 sample.
Overall, there were no observed differences among treat-
ment groups in the incidence of ADAs, time of ADA emer-
gence or ADA titres. Most (∼83%) of the 42 postdose
samples that tested positive for ADAs also tested positive
in the cross-reactivity assay with similar titres. None of the
samples testing positive for ADAs was positive for neutraliz-
ing activity on the cell-based Nab assays.
In general, patients who tested positive for ADAs ap-
peared to have lower AUC0–∞ and higher CL compared with
patients who did not have any samples testing positive for
ADAs (Figure 2); however, the effect of ADA formation
appeared to be comparable among the treatment groups as
there were no apparent differences in group mean (±SD)
estimates of the PK parameters. Overall, ADA development
had no apparent effect on CD19+ B cell depletion/repletion
proﬁles. For the two patients with persistent ADAs and the
highest titres, one (administered rituximab-EU) had CD19+
B cells depleted postdose for the entire study duration – up
to day 169 – whereas the other patient (administered PF-
05280586) had CD19+ B cell counts postdose that became
detectable again after day 85 and reached approximately 5%
of the pretreatment baseline counts on day 141.Safety
Safety data from all 220 patients enrolled were evaluated. Over-
all, no clinically meaningful differences in the incidence or136 Br J Clin Pharmacol (2016) 82 129–138severity of AEs were found among groups (Table 4). A total of
136 (61.8%) patients experienced a treatment-emergent AE [n =
50 (68.5%), n = 41 (55.4%) and n = 45 (61.6%) receiving PF-
05280586, rituximab-EUand rituximab-US, respectively]. Across
all treatments, 57 (25.9%) patients experienced a treatment-
related AE [n = 22 (30.1%), n = 17 (23.0%) and n = 18 (24.7%),
respectively).
One death was reported in a 66-year-old female who de-
veloped a presumed bone neoplasm (no histological conﬁr-
mation) 51 days after the ﬁrst dose of PF-05280586. The
patient was discontinued from the study owing to this AE
and subsequently died. The AE was not considered to be
related to the study drug.
The overall incidence of SAEs was consistent with what
might be expected in an RA population. A total of 12
treatment-emergent SAEs occurred in 11 patients. Five PF-
05280586-treated patients had six SAEs: cardiac failure,
intentional self-injury, presumed bone neoplasm, bacterial
arthritis and, in one patient, bacterial sepsis and septic shock.
In the rituximab-EU group, two patients reported SAEs of
(one each) thrombocytopenic purpura and pericarditis. Four
rituximab-US–treated patients had SAEs (one each): cardiac
failure congestive, atrial ﬂutter, pyelonephritis and arthropa-
thy. Two patients had SAEs that were considered to be
treatment related: the thrombocytopenic purpura reported
by a patient in the rituximab-EU group and the case of atrial
ﬂutter in the rituximab-US group.
A total of four (1.8%) patients were withdrawn from treat-
ment owing to an AE: two (2.7%) receiving PF-05280586, one
(1.4%) receiving rituximab-EU and one (1.4%) receiving
rituximab-US. In all, 21 (9.5%) patients experienced an AE
of grade 3 or higher. The incidence of grade 3 or higher AEs
was lower among patients receiving rituximab-EU [n = 1
(1.4%)] compared with rituximab-US [n = 10 (13.7%)] or PF-
05280586 [n = 10 (13.7%)). There were no dose reductions
or temporary discontinuations due to AEs during the study.
Nine patients (n = 5, n = 2 and n = 2, receiving PF-05280586,
rituximab-EU and rituximab-US, respectively) had the
infusion rate reduced owing to an AE. There were no AEs re-
lated to the ADA response (e.g. infusion related or hypersen-
sitivity reactions), and the incidence and types of AEs
observed in those patients who tested positive for ADAs were
Table 4
Summary of treatment-emergent adverse events (all-causality; mITT population)
n (%)
PF-05280586 Rituximab-EU Rituximab-US
n = 73 n = 74 n = 73
Patients with AEs 50 (68.5) 41 (55.4) 45 (61.6)
Patients with treatment-related AEs 22 (30.1) 17 (23.0) 18 (24.7)
Patients with serious AEs 5 (6.8) 1 (1.4) 4 (5.5)
Patients withdrawn from treatment owing to AEs 2 (2.7) 1 (1.4) 1 (1.4)
Patients with AEs grade ≥3 10 (13.7) 1 (1.4) 10 (13.7)
AE, adverse event; mITT, modiﬁed intent-to-treat.
PF-05280586, a potential biosimilar to rituximabsimilar to those in patients testing negative for ADAs. In gen-
eral, the mean changes from baseline in vital signs were small
and no notable differences were observed across groups with
regard to 12-lead electrocardiogram results.Discussion
The primary objective of the present study was to demon-
strate the PK similarity of PF-05280586, rituximab-EU and
rituximab-US in patients with active RA on a background of
methotrexate who had an inadequate response to one or
more TNF antagonist therapies, using the standard bioequiv-
alence acceptance range of 80.00–125.00%. The 90% CIs for
test-to-reference ratios for the exposure parameters evaluated
were within the predeﬁned acceptance range for comparisons
of PF-05280586 with rituximab-EU and rituximab-US, and
for rituximab-EU compared with rituximab-US, demonstrat-
ing PK similarity among the three products. The PK character-
istics evaluated were consistent with those reported for
rituximab in patients with RA [12].
Baseline CD19+ B cell values were comparable among
the three groups and were similar to previous reports [12].
All three treatments decreased CD19+ B cell counts,
reaching a maximum reduction by week 2. These counts
remained suppressed up to week 25, consistent with previ-
ous reports showing substantial and sustained depletion of
CD19+ B cells following administration of the same doses
of rituximab [12]. There were no major variations in circu-
lating IgM values over time and only small differences were
noted among the groups. Taken together, these results dem-
onstrate that PF-05280586, rituximab-EU and rituximab-US
had comparable CD19+ B cell depletion proﬁles in
patients with active RA on a background of methotrexate
who had an inadequate response to one or more TNF antag-
onist therapies.
The incidence of ADA responses, time of ADA emergence
and ADA titres were similar across treatments. The overall in-
cidence of ADA responses observed was consistent with that
reported (11%) in controlled and long-term studies [5]. The
majority of samples that tested positive for ADAs also tested
positive in the cross-reactivity assay with similar titres, sug-
gesting that ADAs were likely to have developed against
shared epitopes among the study drugs.Overall, no clinically meaningful differences in safety
events were identiﬁed, although some numerical differences
were observed across treatments. Although numerically more
patients receiving PF-05280586 than in the other groups
discontinued the study, no differences were noted in discon-
tinuations due to AEs. Similarly, a numerical difference in
the incidence of grade 3 or above AEs was found across
groups, with a lower incidence occurring in patients receiving
rituximab-EU compared with rituximab-US or PF-05280586.
None of the individual (preferred term) AEs of grade 3 or
higher occurred in more than two patients treated with any
of the three treatments.
In summary, the evidence of PK similarity of PF-05280586
to rituximab-EU and rituximab-US, together with the results
of safety, immunogenicity and PD assessments from the pres-
ent study, support the continued development of PF-
05280586 as a potential biosimilar for rituximab. In addition,
the results of PK similarity between rituximab-EU and
rituximab-US indicated that either of the two products by it-
self can be used a comparator for future comparative studies
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